Introduction
Intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas are characterized as intraductal papillary growths of neoplastic, mucin-producing columnar cells that arise in the main pancreatic duct or its major branches [1] [2] [3] [4] [5] . IPMNs can be subdivided into main duct (MD-IPMN) and branch duct (BD-IPMN) types depending on whether the lesion is located in the main pancreatic duct or the side branch 6, 7 . Various reports have demonstrated that there are significant differences in the presence of cancer between MD-IPMN and BD-IPMN, ranging from 57% to 95% and 6% to 46%, 
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. Consequently, these reports raise the question of whether a pancreas with BD-IPMNs may be at high risk for additional pancreatic cancer. In our present study, we aimed to investigate the development of PDAs in BD-IPMN patients who were followed conservatively. 
Patients and Methods

Definitions
Data Collection and Statistical Analysis
We used age-stratified and sex-specific data on The ratio of the number of observed cases of PDAs in the BD-IPMN patients who were followed to the expected number of cases (standardized incidence ratio (SIR)) was used to estimate the relative risk. The 95% confidence interval (CI) for the SIR was calculated assuming that the observed cases of PDAs followed a Poisson distribution.
Statistical significance was analyzed using the Fisher exact chi-square test. Differences were considered to be significant when the p-value was less than 0.05. All of the statistical tests were two-tailed.
Results
Characteristics of the 89 follow-up patients with BD-IPMNs
Characteristics of the 89 BD-IPMN patients with a follow-up period of more than 2 years are summarized in Table 1 
Development of PDAs in patients with BD-IPMNs during follow-up
After a follow-up period with a median of 63 months (range, 37-92 months), four PDAs (4.5%) metachronously developed in the pancreata apart from the BD-IPMN (Table 2 ). There were no cases with Remaining 75 asymptomatic patients without mural nodules and cystic enlargement, including 17 (22.7%) with a cyst size >30 mm, continued to be followed conservatively, with a median follow-up of 64 months (range, 25-158 months) ( Table 1) .
Risk of PDAs in follow-up patients with BD-IPMN
During the follow-up period of more than two p=0.00014) ( Table 3 ). Subgroup analyses showed that the incidence of PDAs was significantly increased in those ≥70 years of age (SIR 16.7; 95% CI 3.4-48.7; p=0.0008) and in females (SIR 22.5; 95% CI 2.7-81.1; p=0.0037).
The cumulative incidence of PDAs analyzed by the Kaplan-Meier method was 3.0% at 5 years and 8.8% at 10 years ( Figure 1 ). 
Discussion
